Literature DB >> 27976414

Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.

Ye Zhou1, Ben Copeland1, Maya Otto-Duessel1, Miaoling He1, Susan Markel1, Tim W Synold1, Jeremy O Jones1.   

Abstract

BACKGROUND: Low serum testosterone (low T) has been repeatedly linked to worse outcomes in men with newly diagnosed prostate cancer (PC). How low T contributes to these outcomes is unknown. Here we demonstrate that exposure to low T causes significant changes in the mouse prostate and prostate stem cells.
METHODS: Mice were castrated and implanted with capsules to achieve castrate, normal, or sub-physiological levels of T. After 6 weeks of treatment, LC-MS/MS was used to quantify the levels of T and dihydrotestosterone (DHT) in serum and prostate tissue. FACS was used to quantify the percentages of purported prostate stem and transit amplifying (TA) cells in mouse prostates. Prostate tissues were also stained for the presence of CD68+ cells and RNA was extracted from prostate tissue or specific cell populations to measure changes in transcript levels with low T treatment.
RESULTS: Despite having significantly different levels of T and DHT in the serum, T and DHT concentrations in prostate tissue from different T treatment groups were similar. Low T treatment resulted in significant alterations in the expression of androgen biosynthesis genes, which may be related to maintaining prostate androgen levels. Furthermore, the expression of androgen-regulated genes in the prostate was similar among all T treatment groups, demonstrating that the mouse prostate can maintain functional levels of androgens despite low serum T levels. Low T increased the frequency of prostate stem and TA cells in adult prostate tissue and caused major transcriptional changes in those cells. Gene ontology analysis suggested that low T caused inflammatory responses and immunofluorescent staining indicated that low T treatment led to the increased presence of CD68+ macrophages in prostate tissue.
CONCLUSIONS: Low T alters the AR signaling axis which likely leads to maintenance of functional levels of prostate androgens. Low T also induces quantitative and qualitative changes in prostate stem cells which appear to lead to inflammatory macrophage infiltration. These changes are proposed to lead to an aggressive phenotype once cancers develop and may contribute to the poor outcomes in men with low T. Prostate 77:530-541, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  androgen; androgen receptor; low testosterone; prostate cancer; stem cell

Mesh:

Substances:

Year:  2016        PMID: 27976414      PMCID: PMC9135143          DOI: 10.1002/pros.23290

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.012


  56 in total

1.  Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.

Authors:  Takashi Imamoto; Hiroyoshi Suzuki; Satoshi Fukasawa; Masaki Shimbo; Masahiko Inahara; Akira Komiya; Takeshi Ueda; Taizo Shiraishi; Tomohiko Ichikawa
Journal:  Eur Urol       Date:  2004-12-29       Impact factor: 20.096

2.  Is low serum free testosterone a marker for high grade prostate cancer?

Authors:  M A Hoffman; W C DeWolf; A Morgentaler
Journal:  J Urol       Date:  2000-03       Impact factor: 7.450

3.  High-grade prostate cancer is associated with low serum testosterone levels.

Authors:  G Schatzl; S Madersbacher; T Thurridl; J Waldmüller; G Kramer; A Haitel; M Marberger
Journal:  Prostate       Date:  2001-04       Impact factor: 4.104

4.  Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.

Authors:  Yuzo Furuya; Tetsuo Nozaki; Osamu Nagakawa; Hideki Fuse
Journal:  Endocr J       Date:  2002-02       Impact factor: 2.349

Review 5.  The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models.

Authors:  Taija Saloniemi; Heli Jokela; Leena Strauss; Pirjo Pakarinen; Matti Poutanen
Journal:  J Endocrinol       Date:  2011-11-01       Impact factor: 4.286

6.  The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction.

Authors:  Jinrong Cheng; Yue Wu; James L Mohler; Clement Ip
Journal:  Cancer Biol Ther       Date:  2010-06-24       Impact factor: 4.742

7.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors:  Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.

Authors:  S Ishikawa; M S Soloway; R Van der Zwaag; B Todd
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

View more
  1 in total

1.  Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.

Authors:  Ben T Copeland; Juan Du; Sumanta K Pal; Jeremy O Jones
Journal:  Mol Oncol       Date:  2019-10-13       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.